Evidence map›Paper›PMID 24210124›Full record

ArticleVirology2013

Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Diego A Vargas-Inchaustegui, Peng Xiao, Alison E Hogg, Thorsten Demberg, Katherine McKinnon, David Venzon, Egidio Brocca-Cofano, Janet Dipasquale, Eun M Lee, Lauren Hudacik and 6 more

Open access · greenAbstract read
In one paragraph

Article in Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Quantitative PET imaging of the CD4 pool in nonhuman primates.European journal of nuclear medicine and molecular imaging · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. HIV-specific CD8⁺ T cells and HIV eradication.The Journal of clinical investigation · 2016
    Review
  8. Article
  9. Animal models in HIV cure research.Journal of virus eradication · 2015
    Review
  10. Animal models for viral infection and cell exhaustion.Current opinion in HIV and AIDS · 2014
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Diego A Vargas-InchausteguiVaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Peng Xiao
Alison E Hogg
Thorsten Demberg
Katherine McKinnon
David Venzon
Egidio Brocca-Cofano
Janet Dipasquale
Eun M Lee
Lauren Hudacik
Ranajit Pal
Yongjun Sui
Jay A Berzofsky
Linda Liu
Solomon Langermann
Marjorie Robert-Guroff
National Institutes of Health · USAdvanced Bioscience Laboratories (United States) · USAmplimmune (United States) · US

Funding

Vaccine and immunotherapy strategies for cancer and viruses causing cancerZIASC004020 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI BERZOFSKY, JAY A · 2009 to 2025
$51.8M
Development of a Vaccine for HIVAIDS: Cellular ImmunityZIABC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$12.8M
Development of a Vaccine for HIVAIDS: Cellular ImmunityZ01BC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2008 to 2008
$1.3M
Intramural NIH HHS Z01 BC011062
6 · The paper itself

Abstract

High-level T cell expression of PD-1 during SIV infection is correlated with impaired proliferation and function. We evaluated the phenotype and distribution of T cells and Tregs during antiretroviral therapy plus PD-1 modulation (using a B7-DC-Ig fusion protein) and post-ART. Chronically SIV-infected rhesus macaques received: 11 weeks of ART (Group A); 11 weeks of ART plus B7-DC-Ig (Group B); 11 weeks of ART plus B7-DC-Ig, then 12 weeks of B7-DC-Ig alone (Group C). Continuous B7-DC-Ig treatment (Group C) decreased rebound viremia post-ART compared to pre-ART levels, associated with decreased PD-1(hi) expressing T cells and Tregs in PBMCs, and PD-1(hi) Tregs in lymph nodes. It transiently decreased expression of Ki67 and α4β7 in PBMC CD4(+) and CD8(+) Tregs for up to 8 weeks post-ART and maintained Ag-specific T-cell responses at low levels. Continued immune modulation targeting PD-1(hi) cells during and post-ART helps maintain lower viremia, keeps a favorable T cell/Treg repertoire and modulates antigen-specific responses.

Indexed as

AnimalsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveImmunologic FactorsImmunotherapyMacaca mulattaProgrammed Cell Death 1 ReceptorSimian Acquired Immunodeficiency SyndromeT-LymphocytesViral LoadAnti-Retroviral AgentsImmunologic FactorsProgrammed Cell Death 1 ReceptorARTImmunomodulationPD-1TregViremia

Identifiers

PMID24210124
PMCPMC3869407
OpenAlexW2054082838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.